Cost-Effectiveness Analysis of Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China
Chongchong Zhou,1,2,* Jingxuan Wei,1,* Kai Xu,1 Yingtao Lin,3,4 Lingli Zhang,1 Xin Li1,4,5 1Department of Pharmaceutical Regulatory Science and Pharmacoeconomics, School of Pharmacy, Nanjing Medical University, Nanjing, People’s Republic of China; 2Department of Research Management,...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2023-11-01
|
| Series: | Risk Management and Healthcare Policy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/cost-effectiveness-analysis-of-tislelizumab-plus-chemotherapy-as-first-peer-reviewed-fulltext-article-RMHP |